.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Ovarian cancer (OC) remains a major clinical challenge because doctors often diagnose it at advanced stages. At this point, tumor heterogeneity and chemoresistance significantly impact survival rates. However, ovarian cancer organoids derived from ascites now offer a promising way to predict patient responses. These patient-derived organoids (PDOs) mimic the biological complexity of the parental tumor. Consequently, they provide a "living biobank" for precise drug testing.
Researchers recently achieved an 86.2% success rate in establishing these organoid models. Furthermore, whole-exome sequencing confirmed that the PDOs maintained the genomic features of the original cancer. The models accurately predicted how patients would respond to cisplatin and PARP inhibitors during their clinical treatment. This high level of fidelity makes them an ideal platform for personalized oncology.
One of the most exciting findings involves the oncolytic virus OH2. This modified herpes simplex virus 2 directly kills cancer cells, even in cisplatin-resistant cases. Additionally, combining OH2 with cisplatin significantly reduced the CD44+ cancer stem cell population. Since these stem cells often drive recurrence, this combination offers a novel strategy to overcome resistance. Therefore, using PDOs for individualized testing could drastically improve clinical outcomes for ovarian cancer patients.
Current research shows a high success rate of approximately 86.2%, allowing for reliable patient-specific modeling and drug sensitivity testing within a clinically relevant timeframe.
The OH2 virus acts as an oncolytic agent that directly kills cancer cells. Notably, it works synergistically with cisplatin to target and reduce the subpopulation of cancer stem cells that typically cause drug resistance.
Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice or a professional relationship between the reader and the author. Always seek the advice of a qualified healthcare provider for any questions regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.
References
Zhang X et al. Targeting cancer stem cells predicts response and reverses chemoresistance in ascites-derived ovarian cancer organoids. BMC Med. 2026 Feb 24. doi: 10.1186/s12916-026-04730-1. PMID: 41731502.
Nanki K et al. Patient-derived ovarian cancer organoids mimic parental tumor biology and predict drug responses. Nature Communications. 2020;11:4211.
Zhang B et al. Oncolytic herpes simplex virus 2 (OH2) for cancer therapy. Frontiers in Oncology. 2021;11:665555.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Study shows that ascites-derived organoids accurately predict cisplatin response and that OH2 virus combined with chemotherapy targets cancer stem cells....
7 months ago
A retrospective cohort study reveals that frailty quadruples the odds of pressure injuries in hospitalized older adults. Integrating the Clinical Frailty Scale with comprehensive geriatric care is crucial for identifying vulnerability early and implementing targeted multidisciplinary prevention.
Today
Occult maternal malignancy accounts for 3.82% of persistent unreportable NIPT results with genomic noise. Multiple chromosomal aberrations, notably on chromosome 18, warrant thorough oncological evaluation and whole-body MRI to ensure timely maternal diagnosis while preserving fetal care.
Today
This article reviews the forensic and clinical complexities of acute myocarditis arising on left ventricular hypertrophy in children, highlighting early diagnostic red flags and multidisciplinary postmortem autopsy protocols.
Today
A randomized controlled trial demonstrates that an eight-week dual-task training intervention significantly improves static and dynamic postural control over standard balance exercises in individuals with chronic ankle instability, addressing critical neurocognitive deficits during athletic and daily activities.
Today
A retrospective cohort study of 7,716 ICU patients from the MIMIC-IV database demonstrates that Gradient Boosting Decision Trees significantly outperform traditional SOFA scores in predicting in-hospital mortality among patients with sepsis and diabetes, with SHAP analysis providing clinical interpretability.
Today
